Drug Interactions between Pulmicort Turbuhaler and ranitidine
This report displays the potential drug interactions for the following 2 drugs:
- Pulmicort Turbuhaler (budesonide)
- ranitidine
Interactions between your drugs
No interactions were found between Pulmicort Turbuhaler and ranitidine. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Pulmicort Turbuhaler
A total of 563 drugs are known to interact with Pulmicort Turbuhaler.
- Pulmicort turbuhaler is in the drug class inhaled corticosteroids.
- Pulmicort turbuhaler is used to treat Asthma, Maintenance.
ranitidine
A total of 150 drugs are known to interact with ranitidine.
- Ranitidine is in the drug class H2 antagonists.
-
Ranitidine is used to treat the following conditions:
- Cutaneous Mastocytosis
- Duodenal Ulcer
- Duodenal Ulcer Prophylaxis
- Eczema (off-label)
- Erosive Esophagitis
- Gastric Ulcer Maintenance Treatment
- Gastrointestinal Hemorrhage
- GERD
- Hiatal Hernia (off-label)
- Indigestion
- Laryngopharyngeal Reflux (off-label)
- Pathological Hypersecretory Conditions
- Stomach Ulcer
- Stress Ulcer Prophylaxis
- Surgical Prophylaxis
- Urticaria (off-label)
- Zollinger-Ellison Syndrome
Drug and food interactions
budesonide food
Applies to: Pulmicort Turbuhaler (budesonide)
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations and systemic effects of orally administered budesonide. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. According to the manufacturer, the systemic exposure of oral budesonide approximately doubles after extensive intake of grapefruit juice.
MANAGEMENT: Patients receiving budesonide should avoid the regular consumption of grapefruits and grapefruit juice to prevent undue increases in plasma budesonide levels and systemic effects.
References (1)
- (2001) "Product Information. Entocort (budesonide)." AstraZeneca Pharma Inc
raNITIdine food
Applies to: ranitidine
H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.
References (1)
- Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM (1990) "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol, 38, p. 165-9
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.